Literature DB >> 9640213

Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer.

J A van Laar1, Y M Rustum, S P Ackland, C J van Groeningen, G J Peters.   

Abstract

Despite more than 30 years of intensive studies on new drugs against advanced colorectal cancer, the fluoropyrimidines remain the drugs of choice for systemic treatment and for hepatic artery infusion (HAI). This overview describes new developments in advanced colorectal cancer chemotherapy, providing a rationale for more effective use of the fluoropyrimidines, with biochemical modulation, scheduling or by revealing biochemical mechanisms of action that correlate with antitumour activity. In human colorectal cancer cell lines and various animal tumour model systems 5-fluoro-2'-deoxyuridine (FdUrd) is more effective than 5-fluorouracil (5-FU). Comparably, FdUrd's modulation by leucovorin (LV) is more potent than 5-FU. In animal studies it is shown that intermittent high-bolus administration of FdUrd generates better antitumour activity, compared with equal toxic doses or any other schedule of 5-FU. These effects are related to prolonged-thymidylate synthase (TS) inhibition and the prevention of TS induction, rather than RNA incorporation. Preclinical studies with modulators such as N-phosphonacetyl-L-aspartate (PALA), WR-2721, mitomycin C and platinum derivatives provide a rationale for clinical use in the future. The first choice systemic chemotherapy of patients with advanced colorectal cancer remains 5-FU combined with LV. Some improvement in therapeutic efficacy has been achieved with locoregional HAI. In randomised studies HAI FdUrd improves the quality of life and survival as compared with optimal systemic therapy. Chronomodulation decreases toxicity, allowing dose intensification, while modulators such as LV or dexamethasone increase survival of patients treated with HAI FdUrd to 86% after 1 year. In conclusion, the clinical use of FdUrd has not been fully explored. Intermittent high-dose FdUrd, chronomodulation together with the use of modulators or drugs focused on prolonged TS inhibition, should be studied in large randomised studies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9640213     DOI: 10.1016/s0959-8049(97)00366-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  30 in total

1.  Overall survival or other clinical benefits from adjuvant selective intraarterial chemotherapy in patients undergoing curative liver resection for metastatic colorectal tumor.

Authors:  P A Clavien; M Selzner; M A Morse
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

2.  MLH1 deficiency enhances radiosensitization with 5-fluorodeoxyuridine by increasing DNA mismatches.

Authors:  Sheryl A Flanagan; Christina M Krokosky; Sudha Mannava; Mikhail A Nikiforov; Donna S Shewach
Journal:  Mol Pharmacol       Date:  2008-06-05       Impact factor: 4.436

3.  The re-birth of hepatic arterial infusion for colorectal liver metastases.

Authors:  Nancy E Kemeny
Journal:  J Gastrointest Oncol       Date:  2013-06

4.  White light-mediated Cu (II)-5FU interaction augments the chemotherapeutic potential of 5-FU: an in vitro study.

Authors:  Sandesh Chibber; Mohd Farhan; Iftekhar Hassan; Imrana Naseem
Journal:  Tumour Biol       Date:  2011-05-27

5.  Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism.

Authors:  Christopher P Landowski; Xueqin Song; Philip L Lorenzi; John M Hilfinger; Gordon L Amidon
Journal:  Pharm Res       Date:  2005-08-24       Impact factor: 4.200

6.  A new class of 5-fluoro-2'-deoxyuridine prodrugs conjugated with a tumor-homing cyclic peptide CNGRC by ester linkers: synthesis, reactivity, and tumor-cell-selective cytotoxicity.

Authors:  Zhouen Zhang; Hiroshi Hatta; Kazuhito Tanabe; Sei-ichi Nishimoto
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

Review 7.  DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets.

Authors:  Long Shan Li; Julio C Morales; Martina Veigl; David Sedwick; Sheldon Greer; Mark Meyers; Mark Wagner; Richard Fishel; David A Boothman
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

8.  Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cells.

Authors:  Henry Ogbomo; Martin Michaelis; Denise Klassert; Hans Wilhelm Doerr; Jindrich Cinatl
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

9.  Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis.

Authors:  Balvinder S Vig; Philip J Lorenzi; Sachin Mittal; Christopher P Landowski; Ho-Chul Shin; Henry I Mosberg; John M Hilfinger; Gordon L Amidon
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

10.  Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability.

Authors:  Yasuhiro Tsume; John M Hilfinger; Gordon L Amidon
Journal:  Mol Pharm       Date:  2008-07-25       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.